Search academic texts

Information × Registration Number 0212U000234, 0109U001128 , R & D reports Title To substantiate and work up differentiated approaches to treatment of heart failure in patients with type 2 diabetes mellitus popup.stage_title Head Volkov Volodymyr Ivanovych, Registration Date 25-01-2012 Organization State organization "Therapy Institute named after L.T. Malaya of Ukrainian Academy of Medical Sciences" popup.description2 Research object: patients with heart failure (HF) and type 2 diabetes mellitus (DM) and without it. Methods: clinical, instrumental, immunobiochemical. Results: It was found that HF in patients with type 2 DM is characterized by a more pronounced metabolic disorders, imunoinflammatory activation, oxidative stress and imbalance in the system proteinase - proteinase inhibitor. When comparing the effects of statins noted that the results of annual surveillance of hospitalizations for worsening HF in the simvastatin and atorvastatin groups were virtually identical and depended on base line immune lipoproteincontein complexes of IgA. But when using simvastatin was noted more improvement of the clinical condition of patients, systolic and diastolic left ventricular function, against a background of greater weakening signs of oxidative stress and inflammatory activation. Carvedilol, unlike bisoprolol helped reduce insulin resistance and oxidative stress, levels of tumor necrosis factor-alpha, endoteliy dependent improve vasodilation and reduce signs of diastolic dysfunction, left ventricular myocardium. With increased chymase activity additional stabilization of membrane mast cells contributed to significant reduction in activity of proteinases and their inhibitors increase activity, reduce the level of tumor necrosis factor-alpha. These positive changes were accompanied by significant enhancement of clinical effects of standard therapy. In patients with type 2 DM with HF quercetin led to a decrease in oxidative stress, the level of tumor necrosis factor-alpha and help to increase left ventricular ejection fraction, improved clinical and functional status of patients. Product Description popup.authors Бондар. Т.М. Горб. Ю.Г. Комір І.Р. Остапюк О.С. Серік С.А. Сердобінська-Канівець Е.М. Ченчік Т.О. popup.nrat_date 2020-04-02 Close